Akari Therapeutics (AKTX) Competitors $0.76 -0.05 (-5.82%) Closing price 08/29/2025 03:57 PM EasternExtended Trading$0.78 +0.02 (+2.50%) As of 08/29/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. COYA, IOBT, EQ, ADAG, BMEA, ANEB, MGNX, SAVA, TCRX, and ANROShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Coya Therapeutics (COYA), IO Biotech (IOBT), Equillium (EQ), Adagene (ADAG), Biomea Fusion (BMEA), Anebulo Pharmaceuticals (ANEB), MacroGenics (MGNX), Cassava Sciences (SAVA), TScan Therapeutics (TCRX), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Coya Therapeutics IO Biotech Equillium Adagene Biomea Fusion Anebulo Pharmaceuticals MacroGenics Cassava Sciences TScan Therapeutics Alto Neuroscience Coya Therapeutics (NASDAQ:COYA) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Do institutionals & insiders have more ownership in COYA or AKTX? 39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by insiders. Comparatively, 38.1% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is COYA or AKTX more profitable? Coya Therapeutics' return on equity of -61.05% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -61.05% -53.61% Akari Therapeutics N/A -78.03%-31.62% Which has stronger earnings & valuation, COYA or AKTX? Coya Therapeutics has higher revenue and earnings than Akari Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.55M30.92-$14.88M-$1.24-5.29Akari TherapeuticsN/AN/A-$19.79MN/AN/A Do analysts rate COYA or AKTX? Coya Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 151.52%. Akari Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 557.89%. Given Akari Therapeutics' higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, COYA or AKTX? Coya Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Does the media favor COYA or AKTX? In the previous week, Coya Therapeutics had 5 more articles in the media than Akari Therapeutics. MarketBeat recorded 9 mentions for Coya Therapeutics and 4 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 1.22 beat Coya Therapeutics' score of 0.69 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Coya Therapeutics Positive Akari Therapeutics Positive SummaryCoya Therapeutics beats Akari Therapeutics on 6 of the 11 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.46M$3.08B$5.69B$9.74BDividend YieldN/A2.28%6.64%4.48%P/E RatioN/A20.9283.1926.59Price / SalesN/A352.35515.16159.07Price / CashN/A43.5325.6628.92Price / Book0.909.7811.766.08Net Income-$19.79M-$54.01M$3.27B$265.93M7 Day Performance-14.12%0.10%1.13%0.36%1 Month Performance-24.75%8.52%8.30%5.58%1 Year Performance-80.16%7.03%62.26%19.67% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics3.4579 of 5 stars$0.76-5.8%$5.00+557.9%-80.2%$24.46MN/A0.009Positive NewsCOYACoya Therapeutics1.7581 of 5 stars$6.50-5.2%$16.50+153.8%+8.8%$114.73M$3.55M-5.246High Trading VolumeIOBTIO Biotech2.5623 of 5 stars$1.71-1.7%$8.67+406.8%+5.3%$114.63MN/A-1.0830EQEquillium1.0155 of 5 stars$1.90flat$1.00-47.4%+62.6%$113.06M$16.55M-3.3940ADAGAdagene2.9181 of 5 stars$2.35-1.7%$7.00+197.9%-23.9%$112.59M$100K0.00260Gap DownBMEABiomea Fusion3.5657 of 5 stars$1.81-1.1%$16.80+828.2%-73.4%$108.90MN/A-0.6050News CoverageANEBAnebulo Pharmaceuticals2.1351 of 5 stars$2.70+3.8%$5.50+103.7%+30.2%$106.82MN/A-10.384News CoverageMGNXMacroGenics4.3782 of 5 stars$1.64-3.0%$3.60+119.5%-49.6%$106.82M$149.96M-2.88430SAVACassava Sciences2.0341 of 5 stars$2.16-1.8%$2.00-7.4%-92.1%$106.28MN/A-0.8530Positive NewsTCRXTScan Therapeutics3.2472 of 5 stars$1.90+1.6%$7.80+310.5%-68.0%$106.12M$2.82M-1.74100Positive NewsANROAlto Neuroscience2.2144 of 5 stars$3.93+0.8%$8.50+116.3%-71.1%$105.60MN/A-1.64N/A Related Companies and Tools Related Companies Coya Therapeutics Competitors IO Biotech Competitors Equillium Competitors Adagene Competitors Biomea Fusion Competitors Anebulo Pharmaceuticals Competitors MacroGenics Competitors Cassava Sciences Competitors TScan Therapeutics Competitors Alto Neuroscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKTX Stock Alerts